Inclusion Criteria:  Male or female patients 19 ≤ age < 65 years At least 1 year of schizophrenia diagnosed according to DSM-5 criteria(295.90) At least 1 psychotic episode within 1 year Current psychotic episode(acute exacerbation of schizophrenia) within 2 weeks 80 ≤ PANSS total score ≤ 120 Rating of at least 4(moderate) on at least 2 of the following 4 PANSS positive symptoms CGI-S score ≥ 4 Patients who can be hospitalized during the screening period and at least 3 weeks of the initial double-blind treatment phase  Exclusion Criteria:  Psychiatric Criteria  Medical history except schizophrenia specified in protocol First-episode psychosis Treatment-resistant schizophrenia within 2 years Positive result from the blood alcohol concentration(BAC) test or the urine drug screen(UDS) Have suicide risk  Treatment-related Criteria  Electroconvulsive therapy(ECT) within 12 weeks or Previous lack of response to ECT Concomitant treatment with 3 or more antipsychotics within 12 weeks Treatment with flunitrazepam or LAI antipsychotics less than 1 cycle or clozapine within 24 weeks Treatment with CYP3A4 inducers or potent CYP3A4 inhibitors Treatment with amiodarone or systemic corticosteroids for ≥ 12 weeks within 1 year Required prohibited concomitant medication during the study period Prior participation in any clinical trials of Cariprazine  Other  Ophthalmic medical findings or related history(ex. uncontrolled diabetes or hypertension) Abnormal laboratory findings specified in protocol Not suitable for any other reason, as judged by the investigator